Travere Therapeutics (TVTX) Set to Announce Quarterly Earnings on Monday

Travere Therapeutics (NASDAQ:TVTX) is scheduled to issue its quarterly earnings data after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of ($0.98) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Thursday, February 15th. The company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.11. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%. The company had revenue of $45.06 million during the quarter, compared to the consensus estimate of $41.25 million. On average, analysts expect Travere Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Travere Therapeutics Trading Up 1.6 %

Shares of TVTX stock opened at $6.26 on Friday. The stock has a market capitalization of $476.45 million, a price-to-earnings ratio of -3.83 and a beta of 0.69. The company’s fifty day simple moving average is $7.10 and its two-hundred day simple moving average is $7.61. Travere Therapeutics has a 1 year low of $5.12 and a 1 year high of $19.54. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.47 and a quick ratio of 3.41.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on TVTX shares. Piper Sandler increased their price objective on Travere Therapeutics from $10.00 to $11.00 and gave the stock a “neutral” rating in a report on Thursday, January 18th. Guggenheim restated a “neutral” rating on shares of Travere Therapeutics in a research report on Wednesday, March 27th. Wedbush reiterated an “outperform” rating and issued a $13.00 target price on shares of Travere Therapeutics in a research note on Wednesday, April 17th. Wells Fargo & Company raised their price target on shares of Travere Therapeutics from $8.00 to $9.00 and gave the company an “equal weight” rating in a report on Friday, February 16th. Finally, HC Wainwright upped their price target on shares of Travere Therapeutics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $18.00.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.